More on Hologic (HOLX): FQ4 beats Street estimates on the strength of recent acquisitions plus...

|By:, SA News Editor

More on Hologic (HOLX): FQ4 beats Street estimates on the strength of recent acquisitions plus solid sales growth in all its business units. A double-digit jump in breast-health and diagnostic equipment sales helped drive a 9% Y/Y increase in revenue. Shares +3.8% AH.